Dmitrij Hristodorov

Summary

Affiliation: RWTH Aachen
Country: Germany

Publications

  1. pmc Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen 52074, Germany
    Toxins (Basel) 4:676-94. 2012
  2. doi Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Br J Haematol 164:251-7. 2014
  3. doi Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein
    Hannes Brehm
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Cancer Lett 365:149-55. 2015
  4. doi Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells
    Sonja Schiffer
    Department of Experimental Medicine and Immunotherapy, RWTH Aachen, Institute for Applied Medical Engineering, Aachen, Germany Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany
    Cancer Lett 341:178-85. 2013
  5. doi EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Mol Cancer Ther 13:2194-202. 2014

Collaborators

  • Stefan Barth
  • Hannes Brehm
  • Rainer Fischer
  • Radoslav Mladenov
  • Sonja Schiffer
  • Alessa Pardo
  • Mehmet K Tur
  • Judith Niesen
  • Edgar Jost
  • Soriba Letzian
  • Michael Huhn
  • Theo Thepen

Detail Information

Publications5

  1. pmc Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen 52074, Germany
    Toxins (Basel) 4:676-94. 2012
    ..In this review, we focus on the role of different polarized macrophages and the potential of CD64-based IT to intervene in the process of chronic inflammation...
  2. doi Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Br J Haematol 164:251-7. 2014
    ..Our data present a novel approach for the treatment of CD30(+) lymphomas, combining the binding specificity of a target-specific antibody fragment with the selective cytotoxicity of MAPT towards proliferating lymphoma cells. ..
  3. doi Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein
    Hannes Brehm
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Cancer Lett 365:149-55. 2015
    ..We also confirmed that scFv35-MAP induces apoptosis in FL-OH1 and RD cells. The in vivo potential of scFv35-MAP will need to be considered in further studies. ..
  4. doi Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells
    Sonja Schiffer
    Department of Experimental Medicine and Immunotherapy, RWTH Aachen, Institute for Applied Medical Engineering, Aachen, Germany Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany
    Cancer Lett 341:178-85. 2013
    ..In conclusion, granzyme M is a promising new cell-death inducing component for hCFPs because it specifically and efficiently kills target cells when fused to a targeting component...
  5. doi EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Mol Cancer Ther 13:2194-202. 2014
    ..In conclusion, our data suggest that anti-EpCAM(scFv)-MAP may be of therapeutic value for the targeted elimination of EpCAM(+) carcinomas...